Ratings Oculis Holding AG

Equities

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
11.9 ^USD	0.00%		-0.63%	+5.97%

May. 08	Oculis Holding AG Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 24	H.C. Wainwright Adjusts Price Target on Oculis Holding to $28 From $29, Keeps Buy Rating	MT

From a short-term investment perspective, the company presents a deteriorated fundamental situation

The prospective high growth for the next fiscal years is among the main assets of the company
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

	1st Jan change	Capi.	ESG Refinitiv
OCULIS HOLDING AG	+5.97%	495M	-
MODERNA, INC.	+67.53%	63.85B	B-
IQVIA HOLDINGS INC.	-0.77%	41.83B	B
LONZA GROUP AG	+45.66%	40.65B	A
CELLTRION, INC.	-10.72%	27.12B	C
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B	B-
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B	B
BIO-TECHNE CORPORATION	+4.70%	12.73B	B+
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B	B+
MEDPACE HOLDINGS, INC.	+27.41%	12.07B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality